Death

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

Retrieved on: 
Monday, December 12, 2022
Degenerative disease, CSL, Therapy, Biotechnology, Influenza, Vaccination, Iron deficiency, ARCT, Dialysis, CSL Limited, Severe acute respiratory syndrome coronavirus 2, Nephrology, Ageing, Influenza A virus, R, ASX, Infection, CSL Behring, Hospital, Public health, Patient, Immunodeficiency, Disease, Haemophilia, COVID-19, Antibody, History, Death, RNA transfection, Vaccine, H5N1, Innovation, Arcturus Therapeutics, Mortality, CDC, Risk, Pharmaceutical industry, Arcturus

KING OF PRUSSIA, Pa., Dec. 12, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics"; NASDAQ: ARCT). The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.

Key Points: 
  • CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens
    KING OF PRUSSIA, Pa., Dec. 12, 2022 /PRNewswire/ --CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics"; NASDAQ: ARCT).
  • "This is a significant leap forward with a demonstrated platform that will allow us to further explore influenza-adjacent therapies."
  • Today, CSL including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs 30,000 people.
  • CSL Seqirus is part of CSL Limited (ASX: CSL).

SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies : Industry Trends and Global Forecasts, 2022-2040

Retrieved on: 
Monday, December 12, 2022
Molecule, United Nations, Therapy, NIH, Peripheral neuropathy, Neurological disorder, COVID-19 drug development, Amyotrophic lateral sclerosis, Patient, Multiple sclerosis, Glaucoma, Research, Neurodegeneration, Death, Element, CPC, Alzheimer's disease, Geography, Investment, Parkinson's disease, Sterile alpha motif, Vance DeGeneres, Growth, UN, First Nations in Ontario, SARM1, Patent, Organization, Pharmaceutical industry, Fine chemical, Medical device

View original content:https://www.prnewswire.com/news-releases/sarm1-inhibitors-market-by-targ...

Key Points: 
  • In fact, the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone.
  • Additionally, several patents related to SARM1 targeting therapies have been recently filed / granted, demonstrating the continued innovation in this domain.
  • Information on recent developments (partnerships and collaborations, and funding and investments) reported by several players engaged in the SARM1 targeting therapeutics domain.
  • This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments.

Serenus.AI will present a development of an AI-based personalized CDSS for the treatment of Chronic Lymphocytic Leukemia, at the 2022 annual ASH meeting

Retrieved on: 
Monday, December 12, 2022
CLL, American Cancer Society, TEL, Treatment, Prognosis, Physician, Chronic lymphocytic leukemia, Patient, Machine learning, ASH, Death, Research, Medicine, Hospital, Medical device

TEL AVIV, Israel, Dec. 12, 2022 /PRNewswire/ -- Serenus.AI will present its work for the development of an AI-based Personalized CDSS for the Treatment of Chronic Lymphocytic Leukemia (CLL), at the 2022 annual ASH meeting.

Key Points: 
  • TEL AVIV, Israel, Dec. 12, 2022 /PRNewswire/ -- Serenus.AI will present its work for the development of an AI-based Personalized CDSS for the Treatment of Chronic Lymphocytic Leukemia (CLL), at the 2022 annual ASH meeting.
  • The work is the result of a collaboration with J-C Health Care Ltd Israel with the aim to improve outcomes for patients living with CLL.
  • The American Cancer Society estimates that in 2022 about 20,160 new cases of CLL were diagnosed, with estimated deaths of 4,410 persons1.
  • Serenus.AI is an innovative startup that developed a patented AI-based system for personalized medical treatment pathways.

One in Two Patients Tested Misuse Prescription Drugs, Finds 10th Annual Quest Diagnostics Health Trends® Report

Retrieved on: 
Monday, December 12, 2022
Drug, Benzodiazepine, Soul food health trends, Physician, DGX, Cocaine, Substance-related disorder, Bias, Female, Drug overdose, Fentanyl, Public health, Health, Patient, Quest Diagnostics, Population Health Management, Cancer, Illegal drug trade, Privacy, Hospital, Therapeutic drug monitoring, NYSE, Diabetes, Asthma, Policy, DTI, Allergy, Lyme disease, COVID-19, Roger Hawkins (drummer), Death, Multimedia, Degenerative disease, Safety, Hepatitis, Database, CDC, Amphetamine, Male, Risk, Pharmaceutical industry, Medical device, Dietary supplement

SECAUCUS, N.J., Dec. 12, 2022 /PRNewswire/ -- Today, Quest Diagnostics (NYSE: DGX) released its latest Health Trends® report, "Drug Misuse in America 2022: A Decade Lost to the Drug Crisis." The report, which harnesses insights from more than 20 million clinical drug tests over 10 years, shows that while progress has been made in the last decade of drug misuse, patients of all ages and both sexes are still at risk.

Key Points: 
  • To access the Health Trends report, visit Quest Diagnostics Newsroom - Health Trends .
  • In 2021, nearly half (49%) of people tested showed evidence of prescription drug misuse, compared to 60% in 2012.
  • "This year's Quest Diagnostics Health Trends Report underscores the deeply entrenched pattern of prescription drug misuse," said report co-author Harvey W. Kaufman, M.D., Senior Medical Director and Head of the Health Trends Research Program for Quest Diagnostics.
  • Quest Diagnostics Health Trends is a series of scientific reports that provide insights into health issues, based on patient laboratory data, to empower better patient care, population health management and public health policy.

Family Files Wrongful Death Lawsuit Claiming Georgia Father Died From Drinking Kratom

Retrieved on: 
Monday, December 12, 2022
Drinking, Food, Sellers, CDP, Sale, Death, Complaint, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Trauma, CPR, News, McPherson, Marketing, Grief, Drug, Ridesharing company, Tobacco

ATLANTA, Dec.12, 2022 /PRNewswire-PRWeb/ -- A Georgia man's family filed a wrongful death lawsuit claiming he died from drinking kratom. The lawsuit says that on November 19, 2020, Peter McPherson began shaking uncontrollably at the dinner table and fell down unconscious. His wife and son "performed CPR on him for 15 minutes." Peter was taken to Murray County Hospital, where he was later pronounced dead. The Gordon County medical examiner's toxicology report shows high levels of mitragynine.

Key Points: 
  • The attorneys at mctlaw have filed a wrongful death lawsuit on the family's behalf alleging kratom caused his death.
  • ATLANTA, Dec.12, 2022 /PRNewswire-PRWeb/ -- A Georgia man's family filed a wrongful death lawsuit claiming he died from drinking kratom.
  • The lawsuit says that on November 19, 2020, Peter McPherson began shaking uncontrollably at the dinner table and fell down unconscious.
  • The Lawsuit Against the Kratom Manufacturers, Distributors, and Sellers
    The lawsuit alleges that the kratom products manufactured, distributed, and sold by the defendants are responsible for the death of husband and father, Peter McPherson.

Viewpoint to produce an upcoming segment discussing Diabetes, hosted by Dennis Quaid

Retrieved on: 
Friday, December 9, 2022
Diabetes, Death, Disease, Oregon Youth Development Division, Organization, Prevalence, Quality of life, Disease management, Research, Viewpoint, Pharmaceutical industry

MIAMI, Dec. 9, 2022 /PRNewswire-PRWeb/ -- The documentary series Viewpoint with Dennis Quaid explores diabetes research and treatment in an upcoming episode. The program will explore disease management with the forerunning leaders in diabetes care. Veteran actor Dennis Quaid will host, opening and closing the segment. Content providers from related organizations are supplying their testimony to create the episode.

Key Points: 
  • The educational series will discuss ways that the diabetes epidemic is being addressed...
    MIAMI, Dec. 9, 2022 /PRNewswire-PRWeb/ -- The documentary series Viewpoint with Dennis Quaid explores diabetes research and treatment in an upcoming episode.
  • Veteran actor Dennis Quaid will host, opening and closing the segment.
  • Viewpoint with Dennis Quaid is an educational program created for sole distribution to television stations.
  • Development Division, Viewpoint with host Dennis Quaid, 561-244-7620, [email protected]

British Swim School Brings Much-Needed Services to Roanoke Valley

Retrieved on: 
Friday, December 9, 2022
Water, International Red Cross and Red Crescent Movement, Drowning, Survival, Swimming, Lake, Education, School, Research, Curriculum, Child, Love, Death, Stroke, Risk, Medicine, Toy, Tutoring, Hospital, Roanoke Valley

ROANOKE, Va., Dec. 9, 2022 /PRNewswire-PRWeb/ -- British Swim School, the North American leader in "learn to swim" franchises, is moving forward with expansion by opening its first location this week in the Roanoke Valley. A second location aims to open in early January.

Key Points: 
  • ROANOKE, Va., Dec. 9, 2022 /PRNewswire-PRWeb/ -- British Swim School , the North American leader in "learn to swim" franchises, is moving forward with expansion by opening its first location this week in the Roanoke Valley.
  • "I could tell right from the get-go that British Swim School's curriculum and their programming was stellar.
  • British Swim School, the nation's most established swim school franchise, with over 40 years in business, believes that every individual, regardless of age or ability, should have the opportunity to become a safe and happy swimmer.
  • Part of the Buzz Franchise Brands family, British Swim School currently operates over 250 schools across the United States and Canada.

Xavier's School Albums Stay Bold or Get Old, B-Sides Death to False Pop Punk on Tummy Rock Records Site

Retrieved on: 
Friday, December 9, 2022
School, Death, Bowl cut, St. Xavier's School, Ranchi, Cassette tape, Nightclub, Weaving

BELLINGHAM, Wash., Dec. 9, 2022 /PRNewswire-PRWeb/ -- After releasing Stay Bold or Get Old and their B-sides album Death to False Pop Punk, the four piece emo pop punk has their albums hosted on the Tummy Rock Records website.

Key Points: 

Video Commerce Leader Firework Releases Key Predictions for 2023

Retrieved on: 
Friday, December 9, 2022
The Fresh Market, Social media, IRL, ROI, Millennials, Language, Creativity, Publishing, RMN Newsletter, Adweek, Research, Strategic partnership, Livestream shopping, Steam, Communication, Livestreaming, Power, Death, Generation Z, Omnichannel, Government, RMN, Senior, Growth, Organization, Tax, Acquisition, Risk, Online shopping, Video game, Retail, Management, Entertainment, Fireworks

NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Video commerce leader Firework today released its top predictions for 2023 to help brands, retailers, and publishers navigate the rapidly changing world of digital engagement and ecommerce.

Key Points: 
  • NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Video commerce leader Firework today released its top predictions for 2023 to help brands, retailers, and publishers navigate the rapidly changing world of digital engagement and ecommerce.
  • Firework's predictions for 2023 include:
    Store associates will be the new Creator class.
  • Firework enters 2023 poised to bolster its position as the world's leading video commerce solution through continued innovation and growth.
  • Firework is the world's leading video commerce solution built for brands.

New collaborative initiative to use the global love of sports to combat hate-fueled extremist violence

Retrieved on: 
Friday, December 9, 2022
United Nations, Tree, Crime, War, Ethnic cleansing, Summit, Q&A, Genocide, Sport, Rosenthal, Game Plan, Harold Wallace Rosenthal, Mass atrocity crimes, Genocide prevention, U.N, History, Death, Bradford Tree of Life Synagogue, First Nations in Ontario, UN, Hatred, Risk, Vaccine, Drug

Rosenthal's two brothers, David and Cecil Rosenthal, were killed in the 2018 hate-fueled attack on Pittsburgh's Tree of Life Synagogue.

Key Points: 
  • Rosenthal's two brothers, David and Cecil Rosenthal, were killed in the 2018 hate-fueled attack on Pittsburgh's Tree of Life Synagogue.
  • That attack by a heavily armed gunman led to the deaths of 11 worshipers and constituted the deadliest antisemitic act in U.S. history.
  • About the Eradicate Hate Global Summit: The Summit is the most comprehensive anti-hate conference in the world.
  • To access the entire "Game Plan" of the U.N. & Eradicate Hate Global Summit Sports Working Group, click here.